Key Insights

Highlights

Treatment Research

4 treatments under study, led by Pd1 Inhibitor

Research Leaders

5 sponsors active, led by Tianjin Medical University Cancer Institute and Hospital

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 1 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
Phase 2 (1)

Trial Status

Recruiting1

Clinical Trials (1)

Showing 1 of 1 trials
NCT06084897Phase 2Recruiting

Radiotherapy in Patients With Metastatic Esophageal Cancer Responding to PD-1 Inhibitor Plus Chemotherapy

Showing all 1 trials

Research Network

Common Treatments

  • Pd1 Inhibitor1
  • Tp Paclitaxel With Cisplatin Or Carboplatin Or Pf Fluoropyrimidine With Cisplatin Or Carboplatin Regimen Depended On Investigators Choice1
  • Consolidation Radiation1
  • Salvage Radiation1

Active Sponsors

  • Tianjin Medical University Cancer Institute and Hospital1
  • Cancer Institute and Hospital, Chinese Academy of Medical Sciences1
  • Hebei Medical University Fourth Hospital1
  • Peking University Cancer Hospital & Institute1
  • Anyang Tumor Hospital1

Top Investigators

Related Conditions

  • Esophageal Neoplasm Metastatic1

Activity Timeline